AOD 9604 5mg

Description

Strength: 5mg
CAS: 221231-10-3
Chemical Formula: C₇₈H₁₂₃N₂₃O₂₃S₂
Molecular weight: 1815.10 g/mol
Peptide Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-OH
Synonyms: AOD-9604, AOD 9604
Storage: Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
Shelf life: 24 months from the manufacturing date.

AOD 9604 peptide is a synthetic peptide fragment derived from human growth hormone (HGH), corresponding to amino acids 177–191. It was engineered to isolate metabolic signaling associated with lipid and glucose regulation while excluding the growth-promoting effects of full-length HGH.

In laboratory research, AOD 9604 has been studied in adipose tissue biology, lipid metabolism, glucose regulation, and fat-oxidation pathways. The compound is supplied as a 5 mg lyophilized powder in a sterile, sealed vial and is intended strictly for laboratory and preclinical research use.

• Molecular formula: C₇₈H₁₂₃N₂₃O₂₃S₂
• Molecular weight: approximately 1,815.1 g/mol
• PubChem CID: 71300630

The peptide is chemically modified with an N-terminal tyrosine residue to enhance stability and contains a disulfide bond between cysteine residues. Research-grade material is typically supplied at ≥99% purity, verified by HPLC and mass spectrometry.

The 5 mg vial format supports controlled experimental design, formulation studies, and dose-range exploration. Researchers who buy AOD 9604 peptide commonly select this presentation for in vitro assays and animal-model investigations.

• Growth hormone–derived fragment: Composed of HGH residues 177–191
• Targeted metabolic research focus: Studied in lipid and glucose metabolism models
• Non-growth signaling profile: Does not stimulate IGF-1 production or systemic growth pathways
• High-purity lyophilized format: Supplied at ≥99% purity for reproducible research
• Convenient research presentation: 5 mg per vial supports repeated experimental preparation
• Primary research applications: Adipocyte biology, metabolic regulation, lipolysis, and glucose handling
• Research-only designation: Institutions that order AOD 9604 peptide must restrict use to approved laboratory environments

AOD 9604 is being studied for its selective interaction with metabolic signaling pathways involved in lipid and glucose metabolism. The peptide is primarily researched for stimulation of lipolysis and inhibition of lipogenesis, while also demonstrating activity in glucose regulation pathways without activating growth hormone–related signaling cascades.

Research indicates that the AOD 9604 peptide exerts metabolic effects through multiple intracellular pathways. Primary mechanisms include:

• β-adrenergic receptor (β3-AR) modulation: Upregulation of suppressed β3-AR expression in adipocytes during obesity, enhancing lipolytic sensitivity and energy expenditure
• AMPK-related signaling pathways: Contribution to metabolic regulation and fatty-acid oxidation
• Growth-independent signaling: Mechanisms operate independently of HGH and IGF-1 pathways, distinguishing AOD 9604 from full-length growth hormone

Because of this profile, AOD 9604 is commonly used in in vitro systems and animal models focused on obesity research, adipocyte signaling, metabolic dysfunction, and energy-balance regulation.

Published preclinical studies have evaluated AOD 9604 at microgram-level doses in animal models, with administration routes varying by experimental design.

Reported research observations include:

• Increased markers of lipolysis
• Reduced fat-mass accumulation in diet-induced obesity models
• Modulation of glucose metabolism parameters
• No measurable activation of growth hormone or IGF-1 pathways

All dosing information reflects laboratory and animal research only. There is no established human dosing, and clinical evidence remains limited.

To preserve peptide stability and integrity:

• Lyophilized powder: Store at –20°C or lower, protected from light and moisture
• Handling: Vials should be removed from cold storage only briefly during handling or aliquoting
• After reconstitution: Refrigerate at 2–8°C and use within 10–14 days
• Stability: Avoid repeated freeze–thaw cycles, which may degrade peptide structure

Although preclinical studies have not reported significant toxicity, the human safety profile remains unestablished. This compound is not approved for medical use and must be handled only in controlled research environments using appropriate laboratory safety procedures.

References

https://pubmed.ncbi.nlm.nih.gov/11713213/

https://pubmed.ncbi.nlm.nih.gov/11146367/

https://jofem.org/index.php/jofem/article/view/213/278

https://www.jofem.org/index.php/jofem/article/view/157/194

https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/

Compliance Notice

This product is intended strictly for laboratory research use. It is not approved for human or veterinary use, diagnosis, treatment, or prevention of disease.